Search hospitals > Kentucky > Louisville
James Graham Brown Cancer Center
Claim this profileLouisville, Kentucky 40202
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Melanoma
297 reported clinical trials
22 medical researchers
Summary
James Graham Brown Cancer Center is a medical facility located in Louisville, Kentucky. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Melanoma and other specialties. James Graham Brown Cancer Center is involved with conducting 297 clinical trials across 238 conditions. There are 22 research doctors associated with this hospital, such as Rebecca Redman, MD, Neal E. Dunlap, Robert C. Martin, MD,PhD,FACS, and Jason Chesney, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Rebecca Redman, MDJames Graham Brown Cancer Center3 years of reported clinical research
Studies Cancer
Studies Squamous Cell Carcinoma
15 reported clinical trials
28 drugs studied
Neal E. DunlapThe James Graham Brown Cancer Center at University of Louisville3 years of reported clinical research
Studies Cancer
Studies Squamous Cell Carcinoma
15 reported clinical trials
36 drugs studied
Robert C. Martin, MD,PhD,FACSUniversity of Louisville6 years of reported clinical research
Studies Pancreatic Cancer
Studies Cancer
9 reported clinical trials
16 drugs studied
Jason Chesney, MDUniversity of Louisville-James Graham Brown Cancer Center1 year of reported clinical research
Studies Melanoma
Studies Cancer
6 reported clinical trials
7 drugs studied
Clinical Trials running at James Graham Brown Cancer Center
Squamous Cell Carcinoma
Breast Cancer
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Oropharyngeal Carcinoma
Melanoma
Laryngeal Cancer
Skin Cancer
Oral Squamous Cell Carcinoma
Pembrolizumab + Radiation vs Chemotherapy + Radiation
for Head and Neck Cancer
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Recruiting1 award Phase 231 criteria
Pre-Surgery Chemotherapy + Surgery & Radiation
for Sinus Cancer
This randomized phase II trial studies how well chemotherapy before surgery and radiation therapy works compared to surgery and radiation therapy alone in treating patients with nasal and paranasal sinus cancer that can be removed by surgery. Drugs used in chemotherapy, such as docetaxel, cisplatin, and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy before surgery and radiation therapy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed and treated with radiation.
Recruiting1 award Phase 2
Chemotherapy + Radiation Therapy
for Head and Neck Cancer
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
Recruiting1 award Phase 2 & 321 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at James Graham Brown Cancer Center?
James Graham Brown Cancer Center is a medical facility located in Louisville, Kentucky. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Melanoma and other specialties. James Graham Brown Cancer Center is involved with conducting 297 clinical trials across 238 conditions. There are 22 research doctors associated with this hospital, such as Rebecca Redman, MD, Neal E. Dunlap, Robert C. Martin, MD,PhD,FACS, and Jason Chesney, MD.